朗格汉斯细胞组织细胞增生症

Histiocyte Society. Langerhans cell histiocytosis: Histiocyte Society evaluation and treatment guidelines. April 2009 [internet publication].

• 全文

Weitzman S, Egeler RM. Histiocytic disorders of children and adults: introduction to the problem, overview, historical perspective and epidemiology (adapted from Favara BE, et al. Med Pediatr Oncol 1997). In: Weitzman S, Egeler RM, eds. Histiocytic disorders of children and adults. Cambridge, UK: Cambridge University Press; 2005:3.

Gadner H, Grois N, Pötschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008 Mar 1;111(5):2556-62.

• 摘要

Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. 2001 May;138(5):728-34.

• 摘要

Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013 Jun 20;121(25):5006-14.

• 全文
• 摘要

1.  Nezelof C, Basset F, Rousseau MF. Histiocytosis X histogenetic arguments for a Langerhans cell origin. Biomedicine. 1973 Sep;18(5):365-71.

• 摘要

2.  Arceci RJ, Longley BJ, Emanuel PD. Atypical cellular disorders. Hematology Am Soc Hematol Educ Program. 2002:297-314.

• 摘要

3.  Histiocyte Society. Langerhans cell histiocytosis: Histiocyte Society evaluation and treatment guidelines. April 2009 [internet publication].

• 全文

4.  Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998 Apr;12(2):327-38.

• 摘要

5.  Weitzman S, Egeler RM. Histiocytic disorders of children and adults: introduction to the problem, overview, historical perspective and epidemiology (adapted from Favara BE, et al. Med Pediatr Oncol 1997). In: Weitzman S, Egeler RM, eds. Histiocytic disorders of children and adults. Cambridge, UK: Cambridge University Press; 2005:3.

6.  Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol. 1999 Dec;17(12):3835-49.

• 摘要

7.  Broadbent V, Gadner H, Komp DM, et al. Histiocytosis syndromes in children: II. Approach to the clinical and laboratory evaluation of children with Langerhans cell histiocytosis. Clinical Writing Group of the Histiocyte Society. Med Pediatr Oncol. 1989;17(6):492-5.

• 摘要

8.  Salotti J, Nanduri V, Pearce MS, et al. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch Dis Child. 2009 May;94(5):376-80.

• 摘要

9.  Carstensen H, Ornvold K. The epidemiology of Langerhans cell histiocytosis in children in Denmark, 1975-89. Med Pediatr Oncol. 1993;21:387-88.

10.  Karis J, Bernstrand C, Fadeel B, et al. The incidence of Langerhans cell histiocytosis in children in Stockholm County, Sweden 1992-2001. Proceedings of the XIX meeting of the Histiocyte Society. Philadelphia, PA: Histiocyte Society; 2003:21.

11.  Berry DH, Becton DL. Natural history of histiocytosis X. Hematol Oncol Clin North Am. 1987 Mar;1(1):23-34.

• 摘要

12.  Stuurman KE, Lau L, Doda W, et al. Evaluation of the natural history and long term complications of patients with Langerhans cell histiocystosis of bone. Proceedings of the XIX meeting of the Histiocyte Society. Philadelphia, PA: Histiocyte Society; 2003.

13.  Arico M, Girschikofsky M, Genereau T, et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer. 2003 Nov;39(16):2341-8.

• 摘要

14.  Broadbent V, Pritchard J, Davies EG, et al. Spontaneous remission of multi-system histiocytosis X. Lancet. 1984 Feb 4;1(8371):253-4.

• 摘要

15.  Willman CL, Busque L, Griffith BB, et al. Langerhans'-cell histiocytosis (histiocytosis X) - a clonal proliferative disease. N Engl J Med. 1994 Jul 21;331(3):154-60.

• 摘要

16.  Schouten B, Egeler RM, Leenen PJ, et al. Expression of cell cycle-related gene products in Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2002 Dec;24(9):727-32.

• 摘要

17.  Betts DR, Leibundgut KE, Feldges A, et al. Cytogenetic abnormalities in Langerhans cell histiocytosis. Br J Cancer. 1998 Feb;77(4):552-5.

• 摘要

18.  Murakami I, Gogusev J, Fournet JC, et al. Detection of molecular cytogenetic aberrations in Langerhans cell histiocytosis of bone. Hum Pathol. 2002 May;33(5):555-60.

• 摘要

19.  Bechan GI, Meeker AK, De Marzo AM, et al. Telomere length shortening in Langerhans cell histiocytosis. Br J Haematol. 2008 Feb;140(4):420-8.

• 摘要

20.  Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010 Sep 16;116(11):1919-23.

• 摘要

21.  Glotzbecker MP, Carpentieri DF, Dormans JP. Langerhans cell histiocytosis: a primary viral infection of bone? Human herpes virus 6 latent protein detected in lymphocytes from tissue of children. J Pediatr Orthop. 2004 Jan-Feb;24(1):123-9.

• 摘要

22.  Glotzbecker MP, Carpentieri DF, Dormans JP. Langerhans cell histiocytosis: clinical presentation, pathogenesis, and treatment from the LCH etiology research group at the Children's Hospital in Philadelphia. UPOJ. 2002;15:67-73.

• 全文

23.  McClain K, Jin H, Gresik V, et al. Langerhans cell histiocytosis: lack of a viral etiology. Am J Hematol. 1994 Sep;47(1):16-20.

• 摘要

24.  Jeziorski E, Senechal B, Molina TJ, et al. Herpes-virus infection in patients with Langerhans cell histiocytosis: a case-controlled sero-epidemiological study, and in situ analysis. PLoS One. 2008 Sep 23;3(9):e3262.

• 摘要

25.  Nicholson HS, Egeler RM, Nesbit ME. The epidemiology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998 Apr;12(2):379-84.

• 摘要

26.  Annels NE, Da Costa CE, Prins FA, et al. Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. J Exp Med. 2003 May 19;197(10):1385-90.

• 摘要

27.  Egeler RM, Favara BE, Laman JD, et al. Abundant expression of CD40 and CD40-ligand (CD154) in paediatric Langerhans cell histiocytosis lesions. Eur J Cancer. 2000 Oct;36(16):2105-100.

• 摘要

28.  Tazi A, Moreau J, Bergeron A, et al. Evidence that Langerhans cells in adult pulmonary Langerhans cell histiocytosis are mature dendritic cells: importance of the cytokine microenvironment. J Immunol. 1999 Sep 15;163(6):3511-5.

• 摘要

29.  Egeler RM, Favara BE, van Meurs M, et al. Differential In situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood. 1999 Dec 15;94(12):4195-201.

• 摘要

30.  Rolland A, Guyon L, Gill M, et al. Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. J Immunol. 2005 Mar 1;174(5):3067-71.

• 摘要

31.  Rosso DA, Karis J, Braier JL, et al. Elevated serum levels of the decoy receptor osteoprotegerin in children with Langerhans cell histiocytosis. Pediatr Res. 2006 Feb;59(2):281-6.

• 摘要

32.  Bernstrand C, Cederlund K, Sandstedt B, et al. Pulmonary abnormalities at long-term follow-up of patients with Langerhans cell histiocytosis. Med Pediatr Oncol. 2001 Apr;36(4):459-68.

• 摘要

33.  Tazi A, Jeroen T, Hiltermann N, et al. Adult lung histiocytosis. In: Weitzman S, Egeler RM, eds. Histiocytic disorders of children and adults. Cambridge, UK: Cambridge University Press; 2005;194.

34.  Bhatia S, Nesbit ME Jr, Egeler RM, et al. Epidemiologic study of Langerhans cell histiocytosis in children. J Pediatr. 1997 May;130(5):774-84.

• 摘要

35.  Gadner H, Grois N, Pötschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008 Mar 1;111(5):2556-62.

• 摘要

36.  Kilpatrick SE, Wenger DE, Gilchrist GS, et al. Langerhans' cell histiocytosis (Histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases. Cancer. 1995 Dec 15;76(12):2471-84.

• 摘要

37.  Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. 2001 May;138(5):728-34.

• 摘要

38.  Lau L, Krafchik B, Trebo MM, et al. Cutaneous Langerhans cell histiocytosis in children under one year. Pediatr Blood Cancer. 2006 Jan;46(1):66-71.

• 摘要

39.  Munn S, Chu AC. Langerhans cell histiocytosis of the skin. Hematol Oncol Clin North Am. 1998 Apr;12(2):269-86.

• 摘要

40.  Donadieu J, Egeler RM, Pritchard J. Langerhans cell histiocytosis: a clinical update. In: Weitzman S, Egeler RM, eds. Histiocytic disorders of children and adults. Cambridge, UK: Cambridge University Press; 2005:110.

41.  Grois N, Potschger U, Prosch H, et al. Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2006 Feb;46(2):228-33.

• 摘要

42.  Grois NG, Favara BE, Mostbeck GH, et al. Central nervous system disease in Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998 Apr;12(2):287-305.

• 摘要

43.  Prayer D, Grois N, Prosch H, et al. MR imaging presentation of intracranial disease associated with Langerhans cell histiocytosis. AJNR Am J Neuroradiol. 2004 May;25(5):880-91.

• 全文
• 摘要

44.  Mogul M, Hartman G, Donaldson S, et al. Langerhans' cell histiocytosis presenting with the superior vena cava syndrome: a case report. Med Pediatr Oncol. 1993;21(6):456-9.

• 摘要

45.  Braier J, Ciocca M, Latella A, et al. Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell histiocytosis. Med Pediatr Oncol. 2002 Mar;38(3):178-82.

• 摘要

46.  McClain K, Ramsay NK, Robison L, et al. Bone marrow involvement in histiocytosis X. Med Pediatr Oncol. 1983;11(3):167-71.

• 摘要

47.  Willis B, Ablin A, Weinberg V, et al. Disease course and late sequelae of Langerhans' cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol. 1996 Jul;14(7):2073-82.

• 摘要

48.  Nanduri V, Titgemeyer C, Brock P. Long term outcome of orbital involvement in Langerhans' cell histiocytosis. Med Pediatr Oncol. 2003;40:176.

49.  Nanduri VR, Pritchard J, Chong WK, et al. Labyrinthine involvement in Langerhans' cell histiocytosis. Int J Pediatr Otorhinolaryngol. 1998 Nov 15;46(1-2):109-15.

• 摘要

50.  Egeler RM, Schipper ME, Heymans HS. Gastrointestinal involvement in Langerhans' cell histiocytosis (Histiocytosis X): a clinical report of three cases. Eur J Pediatr. 1990 Feb;149(5):325-9.

• 摘要

51.  Burnett A, Carney D, Mukhopadhyay S, et al. Thyroid involvement with Langerhans cell histiocytosis in a 3-year-old male. Pediatr Blood Cancer. 2008 Mar;50(3):726-7.

• 摘要

52.  Potepan P, Tesoro-Tess JD, Laffranchi A, et al. Langerhans cell histiocytosis mimicking malignancy: a radiological appraisal. Tumori. 1996 Nov-Dec;82(6):603-9.

• 摘要

53.  Meyer JS, Harty MP, Mahboubi S, et al. Langerhans cell histiocytosis: presentation and evolution of radiologic findings with clinical correlation. Radiographics. 1995 Sep;15(5):1135-46.

• 摘要

54.  Phillips M, Allen C, Gerson P, et al. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009 Jan;52(1):97-101.

• 摘要

55.  Ribeiro MJ, Idbaih A, Thomas C, et al. 18F-FDG PET in neurodegenerative Langerhans cell histiocytosis: results and potential interest for an early diagnosis of the disease.J Neurol. 2008 Apr;255(4):575-80.

• 摘要

56.  Geissmann F, Lepelletier Y, Fraitag S, et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood. 2001 Mar 1;97(5):1241-8.

• 摘要

57.  Donadieu J, Rolon MA, Pion I, et al. Incidence of growth hormone deficiency in pediatric-onset Langerhans cell histiocytosis: efficacy and safety of growth hormone treatment. J Clin Endocrinol Metab. 2004 Feb;89(2):604-9.

• 摘要

58.  Nanduri VR, Bareille P, Pritchard J, et al. Growth and endocrine disorders in multisystem Langerhans' cell histiocytosis. Clin Endocrinol (Oxf). 2000 Oct;53(4):509-15.

• 摘要

59.  Dehner LP. Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol. 2003 May;27(5):579-93.

• 摘要

60.  Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol. 1990 Feb;7(1):19-73.

• 摘要

61.  Wang KH, Cheng CJ, Hu CH, et al. Coexistence of localized Langerhans cell histiocytosis and cutaneous Rosai-Dorfman disease. Br J Dermatol. 2002 Oct;147(4):770-4.

• 摘要

62.  Gadner H, Grois N. The histiocytosis syndromes. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al. Dermatology in general medicine. Vol. II. New York, NY: McGraw-Hill Inc.; 1993:2003-2017.

63.  Abla O, Weitzman S, Minkov M, et al. Diabetes insipidus in Langerhans cell histiocytosis: when is treatment indicated? Pediatr Blood Cancer. 2009 May;52(5):555-6.

• 摘要

64.  ClinicalTrials.gov. LCH-III: treatment protocol of the third international study for Langerhans cell histiocytosis. 2016 [internet publication].

• 全文

65.  Woo KI, Harris GJ. Eosinophilic granuloma of the orbit: understanding the paradox of aggressive destruction responsive to minimal intervention. Ophthal Plast Reconstr Surg. 2003 Nov;19(6):429-39.

• 摘要

66.  Egeler RM, Thompson RC Jr, Voute PA, et al. Intralesional infiltration of corticosteroids in localized Langerhans' cell histiocytosis. J Pediatr Orthop. 1992 Nov-Dec;12(6):811-4.

• 摘要

67.  Titgemeyer C, Grois N, Minkov M, et al. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol. 2001 Aug;37(2):108-14.

• 摘要

68.  Minkov M, Steiner M, Pötschger U, et al. Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry. J Pediatr.2008 Nov;153(5):700-5, 705.e1-2.

• 摘要

69.  Munn SE, Olliver L, Broadbent V, et al. Use of indomethacin in Langerhans cell histiocytosis. Med Pediatr Oncol. 1999 Apr;32(4):247-9.

• 摘要

70.  Farran RP, Zaretski E, Egeler RM. Treatment of Langerhans cell histiocytosis with pamidronate. J Pediatr Hematol Oncol. 2001 Jan;23(1):54-6.

• 摘要

71.  Womer RB, Anunciato KR, Chehrenama M. Oral methotrexate and alternate-day prednisone for low-risk Langerhans cell histiocytosis. Med Pediatr Oncol. 1995 Aug;25(2):70-3.

• 摘要

72.  Weitzman S, Egeler RM. Langerhans cell histiocytosis: update for the pediatrician. Curr Opin Pediatr. 2008 Feb;20(1):23-9.

• 摘要

73.  Mammano S, Candiotto S, Balsano M. Cast and brace treatment of eosinophilic granuloma of the spine: long-term follow-up. J Pediatr Orthop. 1997 Nov-Dec;17(6):821-7.

• 摘要

74.  Gadner H, Ladish S. The treatment of Langerhans cell histiocytosis. In: Weitzman S, Egeler RM, eds. Histiocytic disorders of children and adults. Cambridge, UK: Cambridge University Press; 2005:229-53.

75.  Steen AE, Steen KH, Bauer R, et al. Successful treatment of cutaneous Langerhans cell histiocytosis with low-dose methotrexate. Br J Dermatol. 2001 Jul;145(1):137-40.

• 摘要

76.  McClain KL, Kozinetz CA. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007 Jan;48(1):44-9.

• 摘要

77.  Kwon OS, Cho KH, Song KY. Primary cutaneous Langerhans cell histiocytosis treated with photochemotherapy. J Dermatol. 1997 Jan;24(1):54-6.

• 摘要

78.  Hoeger PH, Nanduri VR, Harper JI, et al. Long term follow up of topical mustine treatment for cutaneous Langerhans cell histiocytosis. Arch Dis Child. 2000 Jun;82(6):483-7.

• 摘要

79.  Krafchik B, Pope E, Walsh SR. Histiocytosis of the skin in children and adults. In: Weitzman S, Egeler RM, eds. Histiocytic disorders of children and adults. Cambridge, UK: Cambridge University Press; 2005:130-153.

80.  Abla O, Egeler RM, Weitzman S. Langerhans cell histiocytosis: current concepts and treatments. Cancer Treat Rev. 2010 Jun;36(4):354-9.

• 摘要

81.  McClain KL, Gonzalez JM, Jonkers R, et al. Need for a cooperative study: pulmonary Langerhans cell histiocytosis and its management in adults. Med Pediatr Oncol. 2002 Jul;39(1):35-9.

• 摘要

82.  Ottaviano F, Finlay JL. Diabetes insipidus and Langerhans cell histiocytosis: a case report of reversibility with 2-chlorodeoxyadenosine. J Pediatr Hematol Oncol. 2003 Jul;25(7):575-7.

• 摘要

83.  Broadbent V, Pritchard J. Diabetes insipidus associated with Langerhans cell histiocytosis: is it reversible? Med Pediatr Oncol. 1997 Apr;28(4):289-93.

• 摘要

84.  Büchler T, Cervinek L, Belohlavek O, et al. Langerhans cell histiocytosis with central nervous system involvement: follow-up by FDG-PET during treatment with cladribine. Pediatr Blood Cancer. 2005 Mar;44(3):286-8.

• 摘要

85.  Watts J, Files B. Langerhans cell histiocytosis: central nervous system involvement treated successfully with 2-chlorodeoxyadenosine. Pediatr Hematol Oncol. 2001 Apr-May;18(3):199-204.

• 摘要

86.  Dhall G, Finlay JL, Dunkel IJ, et al. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer. 2008 Jan;50(1):72-9.

• 摘要

87.  Imashuku S, Ishida S, Koike K, et al. Cerebellar ataxia in pediatric patients with Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2004 Nov;26(11):735-9.

• 摘要

88.  Idbaih A, Donadieu J, Barthez MA, et al. Retinoic acid therapy in "degenerative-like" neuro-Langerhans cell histiocytosis: a prospective pilot study. Pediatr Blood Cancer. 2004 Jul;43(1):55-8.

• 摘要

89.  Allen CE, Flores R, Rauch R, et al. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer. 2010 Mar;54(3):416-23.

• 摘要

90.  Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013 Jun 20;121(25):5006-14.

• 全文
• 摘要

91.  Ceci A, de Terlizzi M, Colella R, et al. Langerhans cell histiocytosis in childhood: results from the Italian Cooperative AIEOP-CNR-H.X '83 study. Med Pediatr Oncol. 1993;21(4):259-64.

• 摘要

92.  Morimoto A, Ikushima S, Kinugawa N, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer. 2006 Aug 1;107(3):613-9.

• 摘要

93.  Lair G, Marie I, Cailleux N, et al. Langerhans histiocytosis in adults: cutaneous and mucous lesion regression after treatment with thalidomide [in French]. Rev Med Interne. 1998 Mar;19(3):196-8.

• 摘要

94.  Arceci RJ, Brenner MK, Pritchard J. Controversies and new approaches to treatment of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998 Apr;12(2):339-57.

• 摘要

95.  Egeler RM, de Kraker J, Voute PA. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med Pediatr Oncol. 1993;21(4):265-70.

• 摘要

96.  Rodriguez-Galindo C, Kelly P, Jeng M, et al. Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. Am J Hematol. 2002 Mar;69(3):179-84.

• 摘要

97.  Weitzman S, Wayne AS, Arceci R, et al. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the Histiocyte Society and review of the literature. Med Pediatr Oncol. 1999 Nov;33(5):476-81.

• 摘要

98.  Stine KC, Saylors RL, Saccente S, et al. Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004 Jul;43(1):81-4.

• 摘要

99.  Bernard F, Thomas C, Bertrand Y, et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer. 2005 Nov;41(17):2682-9.

• 摘要

100.  Apollonsky N, Lipton JM. Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside. J Pediatr Hematol Oncol. 2009 Jan;31(1):53-6.

• 摘要

101.  Rodriguez-Galindo C, Jeng M, Khuu P, et al. Clofarabine in refractory Langerhans cell histiocytosis. Pediatr Blood Cancer. 2008 Nov;51(5):703-6.

• 摘要

102.  Campbell PK, Abraham A, Jeng M, et al. Use of clofarabine in the treatment of refractory and recurrent multisystem Langerhans cell histiocytosis. Proceedings from the XXVI annual meeting of the Histiocyte Society. Boston, MA: Histiocyte Society; 2010.

103.  Abraham A, Alsultan A, Jeng M, et al. Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis. Pediatr Blood Cancer. 2013 Jun;60(6):E19-22.

• 摘要

104.  Simko SJ, Tran HD, Jones J, et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer. 2014 Mar;61(3):479-87.

• 全文
• 摘要

105.  Donadieu J, Bernard F, van Noesel M, et al. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. 2015 Sep 17;126(12):1415-23.

• 全文
• 摘要

106.  Rosso DA, Amaral D, Latella A, et al. Reduced doses of cladribine and cytarabine regimen was effective and well tolerated in patients with refractory-risk multisystem Langerhans cell histiocytosis. Br J Haematol. 2016 Jan;172(2):287-90.

• 全文
• 摘要

107.  Caselli D, Arico M; EBMT Paediatric Working Party. The role of BMT in childhood histiocytoses. Bone Marrow Transplant. 2008 Jun;41(suppl 2):S8-13.

• 摘要

108.  Veys PA, Nanduri V, Baker KS, et al. Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. Br J Haematol. 2015 Jun;169(5):711-8.

• 摘要

109.  Kieran MW, Cohen KJ, Doz F, et al. Complete radiographic responses in pediatric patients with BRAFV600E–positive tumors including highgrade gliomas: preliminary results of an ongoing phase 1/2a safety and pharmacokinetics (PK) study of dabrafenib. J Clin Oncol. 2014;32:5s(suppl; abstr 10056).

• 全文

110.  Héritier S, Jehanne M, Leverger G, et al. Vemurafenib use in an infant for high-risk Langerhans cell histiocytosis. JAMA Oncol. 2015 Sep;1(6):836-8.

• 全文
• 摘要

111.  Donadieu J, Armari-Alla C, Templier I, et al. First use of vemurafenib in children LCH with neurodegenerative LCH. 30th Annual Histiocyte Society Meeting, Toronto; 2014.

112.  Charles J, Beani JC, Fiandrino G, et al. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation. J Am Acad Dermatol. 2014 Sep;71(3):e97-9.

• 全文
• 摘要

113.  Bubolz AM, Weissinger SE, Stenzinger A, et al. Potential clinical implications of BRAF mutations in histiocytic proliferations. Oncotarget. 2014 Jun 30;5(12):4060-70.

• 全文
• 摘要

114.  Mogulkoc N, Veral A, Bishop PW, et al. Pulmonary Langerhans' cell histiocytosis; radiologic resolution following smoking cessation. Chest. 1999 May;115(5):1452-5.

• 摘要

115.  Dauriat G, Mal H, Thabut G, et al. Lung transplantation for pulmonary Langerhans' cell histiocytosis: a multicenter analysis. Transplantation. 2006 Mar 15;81(5):746-50.

• 摘要

116.  Howarth DM, Gilchrist GS, Mullan BP, et al. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer. 1999 May 15;85(10):2278-90.

• 摘要

117.  Nanduri VR, Lillywhite L, Chapman C, et al. Cognitive outcome of long-term survivors of multisystem Langerhans cell histiocytosis: a single-institution, cross-sectional study. J Clin Oncol. 2003;21:2961-2967.

• 摘要

118.  Braier J, Chantada G, Rosso D, et al. Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution. Pediatr Hematol Oncol. 1999 Sep-Oct;16(5):377-85.

• 摘要

119.  Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. 2004 May;42(5):438-44.

• 摘要

120.  Egeler RM, Neglia JP, Arico M, et al. The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society. Hematol Oncol Clin North Am. 1998 Apr;12(2):369-78.

• 摘要